Winter Hematology Update 2023 Conference Report
[Le contenu qui suit est présenté dans sa langue originale : Anglais]
WHU is a content-rich meeting that provides a forum for Canadian clinicians, trainees, and allied health care professionals to share the latest hematology news with an emphasis on ASH 2022. WHU presentations and panels discuss/address relevant issues and innovations in hematological disease, presented by leading clinical experts and framed from a Canadian perspective.
Chronic Lymphocytic Leukemia
Speaker Dr. Peter Anglin
Panelist Dr. Christine Chen
Recap of Presentation
Overview / Themes
- BTKi upfront and RR
- ALPINE
- Novel combinations – BTKI + BCL2
- Fixed duration
- GLOW and CAPTIVATE
- Genetics / mutational subset analyses
- “Double-refractory” patients – BTKi and BCL2i
- Pirtobrutinib – BRUIN update
- NX-2127
- CARE™ Canadian guidelines
Hodgkin Lymphoma
Speaker Dr. John Kuruvilla
Panelists Dr. Gwynevere Davies & Dr. Peter Anglin
Recap of Presentation
- Targeted therapy IS Frontline
- Echelon-1 Overall Survival
- HDC.1/S1826 Phase III enrolled
- Can we improve our SOC “traditional” therapy?
- Optimizing “ABVD” or “escBEACOPP”
- Can we define best treatment approaches second-line+?
- Multiple regimens
- CCTG HD.11
Indolent Lymphoma
(Follicular and Mantle cell)
Speaker Dr. David MacDonald
Panelist Dr. Ronan Foley
Recap of Presentation
- Results from the Randomized Triangle Trial by the European MCL Network
- A+I (auto SCT + ibrutinib) is superior to A (auto SCT only)
- A (auto SCT) is not superior to I (ibrutinib without auto SCT)
Impact on Canadian Practice
- Control Arm (RCHOP/RDHAP +ASCT) is highly relevant
- FFS is improved with addition of Ibrutinib to SOC
- Uncertain if this would be fundable – there is a signal for OS but we might have to wait and see
- Uncertain how incorporation of BTKi into first-line would impact second line, where BTKi is current SOC (ie sequencing question)
- Note CAR-T currently funded in 3L (after BTKi failure)
- Can this data justify removing ASCT from our 1L SOC?
- ASCT was not superior compared to I-chemo (no ASCT) – but this is somewhat unconventional (ie is it the same as a non-inferiority design?)
Thrombosis
Speaker Dr. Wendy Lim
Panelist Dr. Lori-Ann Linkins
Recap of Presentation
- Advances in our understanding of LMWH dosing for pregnancy prophylaxis and lack of benefit for anticoagulant prophylaxis for preventing pregnancy loss in women with recurrent miscarriage and thrombophilia
ASH # LBA-5 Anticoagulant prophylaxis in pregnancy in women with miscarriage and thrombophilia (ALIFE2 trial)
Quenby S et al.
-
- Association between recurrent miscarriage and inherited thrombophilia, role of anticoagulation to reduce miscarriage and adverse pregnancy outcomes is unclear
Plasma Cell Dyscrasias
Presenter Dr. Keith Stewart
Panelist Dr. Hira Mian
Recap of Presentation
- Advances in Induction Therapy
- Timing of Transplant
- Duration of Maintenance
- Role of MRD testing
- Emergence of T Cell Engagers
- CAR-T
Aggressive B-cell Lymphoma
Speaker Dr. Anca Prica
Panelists Dr. Michael Crump & Dr. Ronan Foley
Recap of Presentation
- Key News out of ASH 2022 in aggressive B-cell lymphoma
- Frontline treatment
- Relapsed/refractory aggressive B-cell lymphoma
- Canadian Perspective
- Today
- (Near) Future
Myeloid Leukemia
Presenter Dr. Dennis Kim
Panelist Dr. Dawn Maze
Recap of Presentation
- Canadian approach for newly diagnosed Acute Myeloid Leukemia (AML)
- CARE™ Canadian AML guidance: Current Diagnostic and Treatment Algorithm (as of Dec 2022)
https://careeducation.ca/reports/care-treatment-guidance-as-of-dec-2022-for-aml-cll-and-hl/
Thank You To Our Sponsors!
(click on sponsor logo below to see booth space)
STATEMENT OF INDEPENDENCE
CARE™ receives funding at arm’s length from multi-industry sponsors, institutions and research associations. Content reflects the opinions, output and analyses of experts, investigators, educators and clinicians (“CARE™ Faculty”), whose activities, while independent, are commercially supported by the noted sponsors. Program content is developed independently of sponsors. This content is intended for educational value only; to make scientific information and opinions available to health professionals, to stimulate thought, and for further investigation.
CARE™ PUBLICATIONS provides educational updates on current trends in medicine. Content reflects the opinions, output and analyses of experts, investigators, educators and clinicians (“CARE™ Faculty”), whose activities, while independent, are commercially supported by the noted sponsor(s). Program content is developed independently of sponsor(s). This content is intended for educational value only; to make scientific information and opinions available to health professionals, to stimulate thought, and further investigation. Decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources. Opinions expressed herein reflect the opinions and analyses of the experts who have authored the material. Support for the distribution of this report was provided by AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Forus Therapeutics, Janssen (Pharmaceutical Companies of Johnson & Johnson), Kite (a Gilead Company), Hoffmann-La Roche and Seagen. Copyright © 2023 by CARE™. All rights reserved. This publication or any portion thereof, in print, electronic copy or any other form, cannot be reproduced without the express written consent of CARE™. Any information, data, analysis, or results reproduced from another source remains the property of its authors. CARE™ is a registered trademark. Canada (Registration No. TMA931,165). United States of America (Registration No. 5,024,819).
